The world of drug discovery definitely kept us on our toes last year. Uncertainty in the market, not helped by the challenges created by changes in US drug pricing and tariffs, led to spending dips and nervousness throughout the sector. SLAS2026 is a key point in the… Read More
Trump’s global tariffs have been ruled illegal by the Supreme Court – but what, if any, effect will the judgment have on pharmaceutical imports? Writing before the start of the Iran war, which is having its own unique impact on the sector, Diana Turner explores how tariffs have so… Read More
Cem Zorlular, CEO of Er-Kim, explains how biotech can turn the new EU pharma package from challenge to opportunity. In 2028, when new legislation takes effect, the European pharmaceutical landscape will undergo its most significant transformation in two decades. For biotechs, the new EU pharma package is… Read More
Patients could soon be reimbursed for ineffective anti-obesity drugs after human omics company Ovation and precision medicine company PrecisionLife partnered to develop a first-of-its-kind test. The collaboration between the companies aims to develop drug-response biomarkers for glucagon-like peptide-1 receptor agonist (GLP-1) therapies. The resulting findings could form the basis… Read More
Biotechnology company Relief Therapeutics has announced a business combination with commercial-stage company NeuroX to create a new digital neurotherapeutics company. The business combination follows approval from Relief’s shareholders, who have also approved a capital increase through the issuance of 140 million new ordinary shares. The business combination is… Read More
Nearly three out of five biopharma professionals (58%) believe their company’s potential is restricted by rigidity in daily strategic decision-making. Research commissioned by Nmblr revealed that strategic misalignment is endemic across the industry, threatening both speed to market and the ability to adapt in real-time. … Read More
Genetic medicines company MeiraGTx has announced a strategic partnership with Eli Lilly to develop and commercialise genetic medicines in ophthalmology. The deal, worth $475 million, will see MeiraGTx grant Lilly worldwide exclusive rights to its AAV-AIPL1 programme for treatment of Leber congenital amaurosis 4 (LCA4). LCA4… Read More
Health technology company myTomorrows has secured $29 million in funding to develop its AI-driven global platform, aiming to bring patients access to innovative therapies. The company aims to develop a platform to bridge the gap between scientific advancement and patient access to pre-approval treatments. This includes drug… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s leading story came from a positive development in biopharma, with top companies… Read More
News round-up for 3 – 7 November by Bruno Quinney, Content Team at DDW. This week’s leading story is a positive development in biopharma, with top companies reporting market growth in Q3 of 2025. Elsewhere, new research could help combat yellow fever and weight loss, while £500,000 was awarded to a… Read More
Biotechnology companies Cue Biopharma and ImmunoScape have entered into a collaboration and license agreement to advance cell therapies for the treatment of solid tumours. Under the agreement, ImmunoScape will develop a novel ‘Seed-and-Boost’ immunotherapy that combines Cue Biopharma’s clinically-validated Immuno-STAT T-cell engagers with ImmunoScape’s proprietary TCRs. The combination therapy is designed to overcome core limitations of existing cell therapies… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, Galapagos announced plans to shelve its cell therapy business and hundreds of… Read More
News round-up for 20 – 24 October by Bruno Quinney, Content Team at DDW. This week’s leading story comes from biotech, with Galapagos announcing plans to shelve its cell therapy business and hundreds of employees set to lose theirjobs. Elsewhere, pharma firms are offering discounts to US… Read More
The DDW Turning Science into Business Symposium will take place in the afternoon on Tuesday 4 November 2025 at the Francis Crick Institute, one of Europe’s biggest biomedical labs, in London, UK. This is a half day conference. Programme 12.30-1.15PM… Read More
FUJIFILM Irvine Scientific, headquartered in Santa Ana, California is to rebrand as FUJIFILM Biosciences as part of a new structure and strategy for the group. FUJIFILM Corporation’s Life Sciences Group says the new names, collaborative strategic focus, and structural alignment reflects its commitment to life sciences. … Read More
Synthego, a supplier of CRISPR solutions, has entered into a purchase agreement with Perceptive Advisors to acquire all the assets of the company on a going-concern basis. To facilitate the sale, the company has voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court of… Read More
